Cite

HARVARD Citation

    Zhu, P. et al. (2021). Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma. Medicine. 100 (4), p. . [Online]. 
  
Back to record